董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christopher Gabrieli | 男 | Director | 57 | 未披露 | 未持股 | 2017-03-31 |
| Edward Fitzgerald | 男 | Director | 62 | 未披露 | 未持股 | 2017-03-31 |
| B. Lynne Parshall | 女 | Director | 63 | 未披露 | 未持股 | 2017-03-31 |
| Elaine Hochberg | 女 | Director | 60 | 未披露 | 未持股 | 2017-03-31 |
| Sandford D. Smith | 男 | Director | 69 | 未披露 | 未持股 | 2017-03-31 |
| Stanley T. Crooke | 男 | Chairman of the Board of Directors | 71 | 未披露 | 未持股 | 2017-03-31 |
| Paula Soteropoulos | 女 | President, Chief Executive Officer and Director | 49 | 340.94万 | 未持股 | 2017-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffrey M. Goldberg | 男 | Chief Operating Officer | 44 | 98.19万 | 未持股 | 2017-03-31 |
| Louis St. L. O'Dea | -- | Chief Medical Officer | 66 | 354.43万 | 未持股 | 2017-03-31 |
| Elizabeth L. Hougen | 女 | Chief Financial Officer | 55 | 未披露 | 未持股 | 2017-03-31 |
| Paula Soteropoulos | 女 | President, Chief Executive Officer and Director | 49 | 340.94万 | 未持股 | 2017-03-31 |
董事简历
中英对照 | 中文 | 英文- Christopher Gabrieli
-
Christopher Gabrieli Gabrieli先生自2016年4月起担任我们的董事会成员。Gabrieli自2014年6月起担任Empower Schools（一家非营利教育创新组织）首席执行官，自2014年5月起担任Bessemer Venture Partners（一家风险投资基金）荣誉合伙人。此前，他曾担任Bessemer公司的合伙人（从1987年到2014年4月），在那里他曾领导他们的生命科学实践，并对Ionis公司进行创始投资。Gabrieli先生从1989年到2006年在Ionis的董事会任职。在Bessemer任职期间，他投资了30多家生命科学和医疗保健公司，包括几家上市公司。Gabrieli先生也是Massachusetts Board of Higher Education的主席和Harvard Graduate School of Education的兼职讲师。
Christopher Gabrieli Mr. Gabrieli has served as a member of our board of directors since April 2016. Since June 2014 Mr. Gabrieli has served as Chief Executive Officer of Empower Schools, a non-profit education innovation organization, and since May 2014 Mr. Gabrieli has served as a Partner Emeritus at Bessemer Venture Partners, a venture capital fund. Previously, from 1987 to April 2014 Mr. Gabrieli was a Partner at Bessemer, where he led their life sciences practice and made a founding investment in Ionis. Mr. Gabrieli served on Ionis' board of directors from 1989 to 2006. During his time at Bessemer, he invested in over thirty life science and health care companies, including several that became publicly traded. Mr. Gabrieli is also the Chairman of the Massachusetts Board of Higher Education and a part-time Lecturer at the Harvard Graduate School of Education. - Christopher Gabrieli Gabrieli先生自2016年4月起担任我们的董事会成员。Gabrieli自2014年6月起担任Empower Schools（一家非营利教育创新组织）首席执行官，自2014年5月起担任Bessemer Venture Partners（一家风险投资基金）荣誉合伙人。此前，他曾担任Bessemer公司的合伙人（从1987年到2014年4月），在那里他曾领导他们的生命科学实践，并对Ionis公司进行创始投资。Gabrieli先生从1989年到2006年在Ionis的董事会任职。在Bessemer任职期间，他投资了30多家生命科学和医疗保健公司，包括几家上市公司。Gabrieli先生也是Massachusetts Board of Higher Education的主席和Harvard Graduate School of Education的兼职讲师。
- Christopher Gabrieli Mr. Gabrieli has served as a member of our board of directors since April 2016. Since June 2014 Mr. Gabrieli has served as Chief Executive Officer of Empower Schools, a non-profit education innovation organization, and since May 2014 Mr. Gabrieli has served as a Partner Emeritus at Bessemer Venture Partners, a venture capital fund. Previously, from 1987 to April 2014 Mr. Gabrieli was a Partner at Bessemer, where he led their life sciences practice and made a founding investment in Ionis. Mr. Gabrieli served on Ionis' board of directors from 1989 to 2006. During his time at Bessemer, he invested in over thirty life science and health care companies, including several that became publicly traded. Mr. Gabrieli is also the Chairman of the Massachusetts Board of Higher Education and a part-time Lecturer at the Harvard Graduate School of Education.
- Edward Fitzgerald
-
Edward Fitzgerald自2017年5月以来一直担任我们的董事会成员。自2016年4月起担任独立业务顾问。从2010年6月至2016年4月，菲茨杰拉德先生担任ARIADPharmaceuticals，Inc.（一家国际生物制药公司）的执行Vice President，首席财务官和财务主管，并于2002年5月至2010年6月担任其高级副总裁，首席财务官和财务主管。从1998年到2002年4月，他担任Altarex，Inc.（一家处于发展阶段的生物技术公司）的高级副总裁，首席财务官和秘书。他从1992年到1997年在BankBoston Corporation的并购集团和消费者贷款集团担任管理职位。他从1989年到1992年是Arthur Andersen&Co.审计和商业咨询实践的合伙人。
Edward Fitzgerald has served as a member of our board of directors since May 2017. He has been an independent business advisor since April 2016. From June 2010 to April 2016 Mr. Fitzgerald served as Executive Vice President, Chief Financial Officer and Treasurer of ARIAD Pharmaceuticals, Inc., an international biopharmaceutical company, and was its Senior Vice President, Chief Financial Officer and Treasurer from May 2002 to June 2010. He was Senior Vice President, Chief Financial Officer and Secretary of AltaRex, Inc., a development stage biotechnology company, from 1998 to April 2002. He held management positions at BankBoston Corporation from 1992 to 1997 in its Mergers & Acquisitions Group and its Consumer Lending Group. He was a partner in the Audit and Business Advisory Practice of Arthur Andersen & Co. from 1989 to 1992. - Edward Fitzgerald自2017年5月以来一直担任我们的董事会成员。自2016年4月起担任独立业务顾问。从2010年6月至2016年4月，菲茨杰拉德先生担任ARIADPharmaceuticals，Inc.（一家国际生物制药公司）的执行Vice President，首席财务官和财务主管，并于2002年5月至2010年6月担任其高级副总裁，首席财务官和财务主管。从1998年到2002年4月，他担任Altarex，Inc.（一家处于发展阶段的生物技术公司）的高级副总裁，首席财务官和秘书。他从1992年到1997年在BankBoston Corporation的并购集团和消费者贷款集团担任管理职位。他从1989年到1992年是Arthur Andersen&Co.审计和商业咨询实践的合伙人。
- Edward Fitzgerald has served as a member of our board of directors since May 2017. He has been an independent business advisor since April 2016. From June 2010 to April 2016 Mr. Fitzgerald served as Executive Vice President, Chief Financial Officer and Treasurer of ARIAD Pharmaceuticals, Inc., an international biopharmaceutical company, and was its Senior Vice President, Chief Financial Officer and Treasurer from May 2002 to June 2010. He was Senior Vice President, Chief Financial Officer and Secretary of AltaRex, Inc., a development stage biotechnology company, from 1998 to April 2002. He held management positions at BankBoston Corporation from 1992 to 1997 in its Mergers & Acquisitions Group and its Consumer Lending Group. He was a partner in the Audit and Business Advisory Practice of Arthur Andersen & Co. from 1989 to 1992.
- B. Lynne Parshall
-
B. Lynne Parshall，自2000年9月起，她担任Isis的董事。自2007年12月起，她担任我们的首席运营官；自1994年6月至2012年12月31日，她担任我们的首席财务官。自1991年11月，她还担任我们的公司秘书，并在公司担任过许多执行性的职务。在加入Isis之前，她在 Cooley LLP（Isis的外部顾问）进行法律实践，自1986年至1991年，她担任其合伙人。她是American, California and San Diego bar associations的成员。她任职于 Regulus Therapeutics, Inc. 和 Cytokinetcs Inc.的董事会，两个都是生物制药公司。在过去的5年里，她曾担任CardioDynamics International Corporation 和 Corautus Genetics Inc.的董事，两个都是生物制药公司。
B. Lynne Parshall has served as a member of our Board of Directors since February 2013. She currently serves as the Chair of the Board of Directors of Akcea Therapeutics, Inc. and is a member of the Board of Directors of Ionis Pharmaceuticals, Inc. Ms. Parshall was employed at Ionis from 1991 to 2017 where she held various positions of increasing responsibility. Prior to joining Ionis, she was a partner at the law firm of Cooley LLP. Ms. Parshall served as a member of the Board of Directors of Regulus Therapeutics Inc. from January 2009 to June 2015 and prior to Regulus’ conversion to a corporation, from November 2007 to January 2009. Ms. Parshall is a member of the Licensing Executives Society and a member of the American, California and San Diego bar associations. She holds a J.D. from Stanford Law School and a B.A. from Harvard University. - B. Lynne Parshall，自2000年9月起，她担任Isis的董事。自2007年12月起，她担任我们的首席运营官；自1994年6月至2012年12月31日，她担任我们的首席财务官。自1991年11月，她还担任我们的公司秘书，并在公司担任过许多执行性的职务。在加入Isis之前，她在 Cooley LLP（Isis的外部顾问）进行法律实践，自1986年至1991年，她担任其合伙人。她是American, California and San Diego bar associations的成员。她任职于 Regulus Therapeutics, Inc. 和 Cytokinetcs Inc.的董事会，两个都是生物制药公司。在过去的5年里，她曾担任CardioDynamics International Corporation 和 Corautus Genetics Inc.的董事，两个都是生物制药公司。
- B. Lynne Parshall has served as a member of our Board of Directors since February 2013. She currently serves as the Chair of the Board of Directors of Akcea Therapeutics, Inc. and is a member of the Board of Directors of Ionis Pharmaceuticals, Inc. Ms. Parshall was employed at Ionis from 1991 to 2017 where she held various positions of increasing responsibility. Prior to joining Ionis, she was a partner at the law firm of Cooley LLP. Ms. Parshall served as a member of the Board of Directors of Regulus Therapeutics Inc. from January 2009 to June 2015 and prior to Regulus’ conversion to a corporation, from November 2007 to January 2009. Ms. Parshall is a member of the Licensing Executives Society and a member of the American, California and San Diego bar associations. She holds a J.D. from Stanford Law School and a B.A. from Harvard University.
- Elaine Hochberg
-
Elaine Hochberg ，2010十二月三十一日起担任公司的执行副总裁和首席商务官。1999十二月至2010十二月，她担任本公司的营销高级副总裁；2007十二月以来，担任首席商务官。她于1997六月加入公司，担任全资子公司森林制药营销副总裁。1998一月，她晋升为公司营销副总裁。1997年加入公司前，她是 Wyeth-Lederle Laboratories的助理副总裁。
Elaine Hochberg has served as a member of the Board since April 2017. Since March 2016 Ms. Hochberg has been a managing partner of Elaran, LLC, a business strategy and management firm. She was an independent consultant from July 2014 to March 2016. Ms. Hochberg served in various senior leadership positions at Forest Laboratories, Inc. from June 1997 to June 2014. Her positions included Executive Vice President, International, Strategic Planning and Government Affairs from December 2013 to June 2014 Executive Vice President, US Sales and Marketing and Chief Commercial Officer from 2010 to November 2013 Senior Vice President, Marketing and Chief Commercial Officer, from 2007 to 2010 Senior Vice President, Marketing from 1999 to 2007 and Vice President, Marketing from 1997 to 1999. Prior to that, Ms. Hochberg worked in various roles at Wyeth-Ayerst Laboratories and Sandoz Pharmaceuticals. She is a board member of Akcea Therapeutics and also serves on the board of several nonprofit organizations in New York City. Ms. Hochberg earned her B.A and M.B.A. from Columbia University. - Elaine Hochberg ，2010十二月三十一日起担任公司的执行副总裁和首席商务官。1999十二月至2010十二月，她担任本公司的营销高级副总裁；2007十二月以来，担任首席商务官。她于1997六月加入公司，担任全资子公司森林制药营销副总裁。1998一月，她晋升为公司营销副总裁。1997年加入公司前，她是 Wyeth-Lederle Laboratories的助理副总裁。
- Elaine Hochberg has served as a member of the Board since April 2017. Since March 2016 Ms. Hochberg has been a managing partner of Elaran, LLC, a business strategy and management firm. She was an independent consultant from July 2014 to March 2016. Ms. Hochberg served in various senior leadership positions at Forest Laboratories, Inc. from June 1997 to June 2014. Her positions included Executive Vice President, International, Strategic Planning and Government Affairs from December 2013 to June 2014 Executive Vice President, US Sales and Marketing and Chief Commercial Officer from 2010 to November 2013 Senior Vice President, Marketing and Chief Commercial Officer, from 2007 to 2010 Senior Vice President, Marketing from 1999 to 2007 and Vice President, Marketing from 1997 to 1999. Prior to that, Ms. Hochberg worked in various roles at Wyeth-Ayerst Laboratories and Sandoz Pharmaceuticals. She is a board member of Akcea Therapeutics and also serves on the board of several nonprofit organizations in New York City. Ms. Hochberg earned her B.A and M.B.A. from Columbia University.
- Sandford D. Smith
-
Sandford D. Smith，自2012年1月起，担任本公司董事。他目前是 Tullis Health Investors的管理合伙人，该公司管理着一个家族的基金和投资，专注投向医疗保健行业。于2012年1月加盟Tullis之前，他于1996-2011年间在Genzyme公司担任了多个高级行政和管理职位，最近是担任国际部执行副总裁及总裁，负责该公司美国以外的商业活动。加入Genzyme之前，1986-1996，他担任 Repligen Corporation的总裁，首席执行官和董事。 1977-1986，他在施贵宝公司担任了多个职务，其中包括制药部业务开发和战略规划副总裁。他目前担任生物制药公司Cytokynetics的董事，以及BioBehavioral Diagnostics Company 的董事（生产和出售神经疾病和精神疾病的诊断与管理技术的私营公司），并担任着波士顿布里格姆妇女医院咨询委员会主席。在过去的五年里，他一直是 Ariad Pharmaceuticals和Nventa Biopharmaceuticals Corporation的董事。他获得了丹佛大学理科学士学位。
Sandford D. Smith has served as a member of our Board of Directors since March 2012. Since December 2011 Mr. Smith has served as Founder and Chairman of Global Biolink Partners. From 1996 to 2011 Mr. Smith held various positions at Sanofi-Genzyme formerly Genzyme Corporation, most recently leading the integration of Genzyme’s international business into Sanofi’s global organization. Prior to that, he served as Executive Vice President of Genzyme Corporation and President of Genzyme International. From 1986 to 1996 Mr. Smith was President, Chief Executive Officer and a member of the Board of Directors of RepliGen Corporation. From 1977 to 1985 Mr. Smith held various positions at Bristol-Myers Squibb, most recently serving as Vice President of Business Development and Strategic Planning for the Pharmaceutical and Nutritional Division. Mr. Smith has served on the Board of Directors of Akcea Therapeutics, Inc. since March 2017 and Neuralstem, Inc. since May 2014. He served on the Board of Directors of Arpicus Biosciences, Inc. from August 2014 to February 2019 Novelion Therapeutics Inc. from November 2016 to March 2017 Aegerion Pharmaceuticals, Inc. from January 2012 to March 2017 and NVenta Biopharmaceuticals Corporation from 2007 to 2009. Mr. Smith earned a B.S. from the University of Denver. - Sandford D. Smith，自2012年1月起，担任本公司董事。他目前是 Tullis Health Investors的管理合伙人，该公司管理着一个家族的基金和投资，专注投向医疗保健行业。于2012年1月加盟Tullis之前，他于1996-2011年间在Genzyme公司担任了多个高级行政和管理职位，最近是担任国际部执行副总裁及总裁，负责该公司美国以外的商业活动。加入Genzyme之前，1986-1996，他担任 Repligen Corporation的总裁，首席执行官和董事。 1977-1986，他在施贵宝公司担任了多个职务，其中包括制药部业务开发和战略规划副总裁。他目前担任生物制药公司Cytokynetics的董事，以及BioBehavioral Diagnostics Company 的董事（生产和出售神经疾病和精神疾病的诊断与管理技术的私营公司），并担任着波士顿布里格姆妇女医院咨询委员会主席。在过去的五年里，他一直是 Ariad Pharmaceuticals和Nventa Biopharmaceuticals Corporation的董事。他获得了丹佛大学理科学士学位。
- Sandford D. Smith has served as a member of our Board of Directors since March 2012. Since December 2011 Mr. Smith has served as Founder and Chairman of Global Biolink Partners. From 1996 to 2011 Mr. Smith held various positions at Sanofi-Genzyme formerly Genzyme Corporation, most recently leading the integration of Genzyme’s international business into Sanofi’s global organization. Prior to that, he served as Executive Vice President of Genzyme Corporation and President of Genzyme International. From 1986 to 1996 Mr. Smith was President, Chief Executive Officer and a member of the Board of Directors of RepliGen Corporation. From 1977 to 1985 Mr. Smith held various positions at Bristol-Myers Squibb, most recently serving as Vice President of Business Development and Strategic Planning for the Pharmaceutical and Nutritional Division. Mr. Smith has served on the Board of Directors of Akcea Therapeutics, Inc. since March 2017 and Neuralstem, Inc. since May 2014. He served on the Board of Directors of Arpicus Biosciences, Inc. from August 2014 to February 2019 Novelion Therapeutics Inc. from November 2016 to March 2017 Aegerion Pharmaceuticals, Inc. from January 2012 to March 2017 and NVenta Biopharmaceuticals Corporation from 2007 to 2009. Mr. Smith earned a B.S. from the University of Denver.
- Stanley T. Crooke
-
Stanley T. Crooke, M.D., Ph.D.，2009年1月我们公司成立，他在我们董事会任职。此前2007年11月以来，他担任Regulus Therapeutics LLC的董事。他加入我们董事会并担任伊希斯的代表并在2009年1月1日或我们创立投资者权利协议时，他按照建立投资者权利协议进行投资（Alnylam和Isis）。他是Isis的创始人，并担任其首席执行官和董事（1989年以来）以及董事长（1991年以来）。他获得贝勒医学院（Baylor College of Medicine） 药物学硕士和博士学位以及巴特勒大学（Butler University）的药物学学士学位。
Stanley T. Crooke is a founder of Ionis and has been Chief Executive Officer and a Director since January 1989. He was elected Chairman of the Board in February 1991. Prior to founding Ionis, from 1980 until January 1989 Dr. Crooke was employed by SmithKline Beckman Corporation, a pharmaceutical company, where his titles included President of Research and Development of SmithKline and French Laboratories. - Stanley T. Crooke, M.D., Ph.D.，2009年1月我们公司成立，他在我们董事会任职。此前2007年11月以来，他担任Regulus Therapeutics LLC的董事。他加入我们董事会并担任伊希斯的代表并在2009年1月1日或我们创立投资者权利协议时，他按照建立投资者权利协议进行投资（Alnylam和Isis）。他是Isis的创始人，并担任其首席执行官和董事（1989年以来）以及董事长（1991年以来）。他获得贝勒医学院（Baylor College of Medicine） 药物学硕士和博士学位以及巴特勒大学（Butler University）的药物学学士学位。
- Stanley T. Crooke is a founder of Ionis and has been Chief Executive Officer and a Director since January 1989. He was elected Chairman of the Board in February 1991. Prior to founding Ionis, from 1980 until January 1989 Dr. Crooke was employed by SmithKline Beckman Corporation, a pharmaceutical company, where his titles included President of Research and Development of SmithKline and French Laboratories.
- Paula Soteropoulos
-
Paula Soteropoulos，自2013年7月开始，一直担任我们监事会的成员。从2013年7月起，Soteropoulos女士还一直担任Moderna Therapeutics, Inc.心脏疗法的商业和战略联盟部门的高级副总裁兼总经理。在这以前，从1992到2013年，Soteropoulos女士曾在Genzyme公司就职，一家生物技术公司，最近担任的职位是罕见心血管疾病部门的副总裁和总经理。Soteropoulos女士持有塔夫斯大学（Tufts University）化学工程学位学士学位和生物化学工程硕士学位，以及弗吉尼亚大学达顿商学院的工商管理研究生院（University of Virginia, Darden Graduate School of Business Administration）的行政管理证书。
Paula Soteropoulos, has served as a member of our Board since July 2013. Ms. Soteropoulos is an executive leader with more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization and company building. She currently serves as the Executive Chairman of Ensoma, a private venture-backed company. Since November 2020 she has served on the Board of Directors of Rallybio, LLC. Since March 2020 she also has served as a Strategic Advisor to 5AM Ventures. From January 2015 through September 2019 she served as President and Chief Executive Officer of Akcea Therapeutics NASDAQ: AKCA. From July 2013 to December 2014 she served as Senior Vice President and General Manager, Cardiometabolic Business and Strategic Alliances at Moderna Therapeutics Inc. Prior to this, Ms. Soteropoulos worked at Genzyme Corporation, a biotechnology company, from 1992 to 2013 most recently as Vice President and General Manager, Cardiovascular, Rare Diseases. Ms. Soteropoulos holds a Bachelor of Science degree in chemical engineering and a Master of Science degree in chemical and biochemical engineering, both from Tufts University, and holds an executive management certificate from the University of Virginia, Darden Graduate School of Business Administration. Ms. Soteropoulos serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University. - Paula Soteropoulos，自2013年7月开始，一直担任我们监事会的成员。从2013年7月起，Soteropoulos女士还一直担任Moderna Therapeutics, Inc.心脏疗法的商业和战略联盟部门的高级副总裁兼总经理。在这以前，从1992到2013年，Soteropoulos女士曾在Genzyme公司就职，一家生物技术公司，最近担任的职位是罕见心血管疾病部门的副总裁和总经理。Soteropoulos女士持有塔夫斯大学（Tufts University）化学工程学位学士学位和生物化学工程硕士学位，以及弗吉尼亚大学达顿商学院的工商管理研究生院（University of Virginia, Darden Graduate School of Business Administration）的行政管理证书。
- Paula Soteropoulos, has served as a member of our Board since July 2013. Ms. Soteropoulos is an executive leader with more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization and company building. She currently serves as the Executive Chairman of Ensoma, a private venture-backed company. Since November 2020 she has served on the Board of Directors of Rallybio, LLC. Since March 2020 she also has served as a Strategic Advisor to 5AM Ventures. From January 2015 through September 2019 she served as President and Chief Executive Officer of Akcea Therapeutics NASDAQ: AKCA. From July 2013 to December 2014 she served as Senior Vice President and General Manager, Cardiometabolic Business and Strategic Alliances at Moderna Therapeutics Inc. Prior to this, Ms. Soteropoulos worked at Genzyme Corporation, a biotechnology company, from 1992 to 2013 most recently as Vice President and General Manager, Cardiovascular, Rare Diseases. Ms. Soteropoulos holds a Bachelor of Science degree in chemical engineering and a Master of Science degree in chemical and biochemical engineering, both from Tufts University, and holds an executive management certificate from the University of Virginia, Darden Graduate School of Business Administration. Ms. Soteropoulos serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University.
高管简历
中英对照 | 中文 | 英文- Jeffrey M. Goldberg
JeffreyM.Goldberg，Goldberg先生于2015年1月加入Akcea担任首席运营官。在加入AKCEA之前，从2012年12月到2014年9月，Goldberg先生是ProteostasisTherapeutics，Inc.的执行领导团队成员，该公司现在是一家专注于神经病学和孤儿疾病的上市生物技术公司，他在该公司担任业务运营的Vice President。在此之前，Goldberg先生在Genzyme和Sanofi S.A.担任了11年多的职责递增的职位，最近担任Sanofi Oncology的助理Vice President和项目主管。
Jeffrey M. Goldberg, Mr. Goldberg joined Akcea as Chief Operating Officer in January 2015. Prior to joining Akcea, from December 2012 to September 2014 Mr. Goldberg was a member of the executive leadership team at Proteostasis Therapeutics, Inc., a now public biotechnology company focusing on neurology and orphan diseases, where he served as Vice President of Business Operations. Prior to that, Mr. Goldberg spent over 11 years in positions of increasing responsibility with Genzyme and Sanofi S.A., most recently as Associate Vice President, Project Head, within Sanofi Oncology.- JeffreyM.Goldberg，Goldberg先生于2015年1月加入Akcea担任首席运营官。在加入AKCEA之前，从2012年12月到2014年9月，Goldberg先生是ProteostasisTherapeutics，Inc.的执行领导团队成员，该公司现在是一家专注于神经病学和孤儿疾病的上市生物技术公司，他在该公司担任业务运营的Vice President。在此之前，Goldberg先生在Genzyme和Sanofi S.A.担任了11年多的职责递增的职位，最近担任Sanofi Oncology的助理Vice President和项目主管。
- Jeffrey M. Goldberg, Mr. Goldberg joined Akcea as Chief Operating Officer in January 2015. Prior to joining Akcea, from December 2012 to September 2014 Mr. Goldberg was a member of the executive leadership team at Proteostasis Therapeutics, Inc., a now public biotechnology company focusing on neurology and orphan diseases, where he served as Vice President of Business Operations. Prior to that, Mr. Goldberg spent over 11 years in positions of increasing responsibility with Genzyme and Sanofi S.A., most recently as Associate Vice President, Project Head, within Sanofi Oncology.
- Louis St. L. O'Dea
LouisSt.L.O’Dea，MB BCH Bao。FRCPC，O’Dea博士于2016年1月加入Akcea担任首席医疗官。在加入AKCEA之前，O’Dea博士于2014年6月至2016年1月担任私人诊断公司Oxford Immunotec Global Plc的首席医疗官，负责医疗事务和临床开发。任职Oxford公司之前，O’Dea博士曾于2012年1月至2014年6月担任Moderna公司的首席医疗官兼监管事务主管。任职Moderna公司之前，O’Dea博士曾担任RadiusHealth，Inc.公司（一家公共生物制药公司）的首席医疗官、麦吉尔大学（McGill University）的学术职位，以及Serono公司内分泌和代谢产品临床开发全球主管。
Louis St. L. O'Dea, MB BCh BAO. FRCPC, Dr. O'Dea joined Akcea as Chief Medical Officer in January 2016. Prior to joining Akcea, Dr. O'Dea was Chief Medical Officer at Oxford Immunotec Global PLC, a private diagnostics company, from June 2014 to January 2016 overseeing medical affairs and clinical development. Prior to Oxford, Dr. O'Dea was Chief Medical Officer and Head of Regulatory Affairs at Moderna from January 2012 to June 2014. Before Moderna, Dr. O'Dea had positions including Chief Medical Officer at Radius Health, Inc., a public biopharmaceuticals company, an academic position at McGill University, and worldwide Head of Clinical Development for Endocrine and Metabolic products at Serono.- LouisSt.L.O’Dea，MB BCH Bao。FRCPC，O’Dea博士于2016年1月加入Akcea担任首席医疗官。在加入AKCEA之前，O’Dea博士于2014年6月至2016年1月担任私人诊断公司Oxford Immunotec Global Plc的首席医疗官，负责医疗事务和临床开发。任职Oxford公司之前，O’Dea博士曾于2012年1月至2014年6月担任Moderna公司的首席医疗官兼监管事务主管。任职Moderna公司之前，O’Dea博士曾担任RadiusHealth，Inc.公司（一家公共生物制药公司）的首席医疗官、麦吉尔大学（McGill University）的学术职位，以及Serono公司内分泌和代谢产品临床开发全球主管。
- Louis St. L. O'Dea, MB BCh BAO. FRCPC, Dr. O'Dea joined Akcea as Chief Medical Officer in January 2016. Prior to joining Akcea, Dr. O'Dea was Chief Medical Officer at Oxford Immunotec Global PLC, a private diagnostics company, from June 2014 to January 2016 overseeing medical affairs and clinical development. Prior to Oxford, Dr. O'Dea was Chief Medical Officer and Head of Regulatory Affairs at Moderna from January 2012 to June 2014. Before Moderna, Dr. O'Dea had positions including Chief Medical Officer at Radius Health, Inc., a public biopharmaceuticals company, an academic position at McGill University, and worldwide Head of Clinical Development for Endocrine and Metabolic products at Serono.
- Elizabeth L. Hougen
Elizabeth L. Hougen，2013年1月，她晋升为财务高级副总裁和首席财务官。自2007年1月至2012年12月，她担任我们的财务副总裁和首席会计官；自2000年5月至2007年1月，她担任我们的财务副总裁。在2000年加入Isis之前，她是 Molecular Biosystems, Inc.的财务执行董事和首席财务官，这是一个上市的生物技术公司。
Elizabeth L. Hougen was promoted to Senior Vice President, Finance and Chief Financial Officer in January 2013. From January 2007 to December 2012 Ms. Hougen served as our Vice President, Finance and Chief Accounting Officer and from May 2000 to January 2007 she served as our Vice President, Finance. Prior to joining Ionis in 2000 Ms. Hougen was Executive Director, Finance and Chief Financial Officer for Molecular Biosystems, Inc., a public biotechnology company.- Elizabeth L. Hougen，2013年1月，她晋升为财务高级副总裁和首席财务官。自2007年1月至2012年12月，她担任我们的财务副总裁和首席会计官；自2000年5月至2007年1月，她担任我们的财务副总裁。在2000年加入Isis之前，她是 Molecular Biosystems, Inc.的财务执行董事和首席财务官，这是一个上市的生物技术公司。
- Elizabeth L. Hougen was promoted to Senior Vice President, Finance and Chief Financial Officer in January 2013. From January 2007 to December 2012 Ms. Hougen served as our Vice President, Finance and Chief Accounting Officer and from May 2000 to January 2007 she served as our Vice President, Finance. Prior to joining Ionis in 2000 Ms. Hougen was Executive Director, Finance and Chief Financial Officer for Molecular Biosystems, Inc., a public biotechnology company.
- Paula Soteropoulos
Paula Soteropoulos，自2013年7月开始，一直担任我们监事会的成员。从2013年7月起，Soteropoulos女士还一直担任Moderna Therapeutics, Inc.心脏疗法的商业和战略联盟部门的高级副总裁兼总经理。在这以前，从1992到2013年，Soteropoulos女士曾在Genzyme公司就职，一家生物技术公司，最近担任的职位是罕见心血管疾病部门的副总裁和总经理。Soteropoulos女士持有塔夫斯大学（Tufts University）化学工程学位学士学位和生物化学工程硕士学位，以及弗吉尼亚大学达顿商学院的工商管理研究生院（University of Virginia, Darden Graduate School of Business Administration）的行政管理证书。
Paula Soteropoulos, has served as a member of our Board since July 2013. Ms. Soteropoulos is an executive leader with more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization and company building. She currently serves as the Executive Chairman of Ensoma, a private venture-backed company. Since November 2020 she has served on the Board of Directors of Rallybio, LLC. Since March 2020 she also has served as a Strategic Advisor to 5AM Ventures. From January 2015 through September 2019 she served as President and Chief Executive Officer of Akcea Therapeutics NASDAQ: AKCA. From July 2013 to December 2014 she served as Senior Vice President and General Manager, Cardiometabolic Business and Strategic Alliances at Moderna Therapeutics Inc. Prior to this, Ms. Soteropoulos worked at Genzyme Corporation, a biotechnology company, from 1992 to 2013 most recently as Vice President and General Manager, Cardiovascular, Rare Diseases. Ms. Soteropoulos holds a Bachelor of Science degree in chemical engineering and a Master of Science degree in chemical and biochemical engineering, both from Tufts University, and holds an executive management certificate from the University of Virginia, Darden Graduate School of Business Administration. Ms. Soteropoulos serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University.- Paula Soteropoulos，自2013年7月开始，一直担任我们监事会的成员。从2013年7月起，Soteropoulos女士还一直担任Moderna Therapeutics, Inc.心脏疗法的商业和战略联盟部门的高级副总裁兼总经理。在这以前，从1992到2013年，Soteropoulos女士曾在Genzyme公司就职，一家生物技术公司，最近担任的职位是罕见心血管疾病部门的副总裁和总经理。Soteropoulos女士持有塔夫斯大学（Tufts University）化学工程学位学士学位和生物化学工程硕士学位，以及弗吉尼亚大学达顿商学院的工商管理研究生院（University of Virginia, Darden Graduate School of Business Administration）的行政管理证书。
- Paula Soteropoulos, has served as a member of our Board since July 2013. Ms. Soteropoulos is an executive leader with more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization and company building. She currently serves as the Executive Chairman of Ensoma, a private venture-backed company. Since November 2020 she has served on the Board of Directors of Rallybio, LLC. Since March 2020 she also has served as a Strategic Advisor to 5AM Ventures. From January 2015 through September 2019 she served as President and Chief Executive Officer of Akcea Therapeutics NASDAQ: AKCA. From July 2013 to December 2014 she served as Senior Vice President and General Manager, Cardiometabolic Business and Strategic Alliances at Moderna Therapeutics Inc. Prior to this, Ms. Soteropoulos worked at Genzyme Corporation, a biotechnology company, from 1992 to 2013 most recently as Vice President and General Manager, Cardiovascular, Rare Diseases. Ms. Soteropoulos holds a Bachelor of Science degree in chemical engineering and a Master of Science degree in chemical and biochemical engineering, both from Tufts University, and holds an executive management certificate from the University of Virginia, Darden Graduate School of Business Administration. Ms. Soteropoulos serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University.